Observational Study of metastatic breast cancer patients

A multi-center, multi-country prospective observational study of patients initiating T-DXd in the first or second treatment line for HER2+, and HER2-low unresectable and/or metastatic breast cancer (DESTINY BREAST- RESPOND) (D9673R00025)

Disease Types: Breast

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A multi-center, multi-country prospective observational study of patients initiating T-DXd in the first or second treatment line for HER2+, and HER2-low unresectable and/or metastatic breast cancer (DESTINY BREAST- RESPOND) (D9673R00025)

For More Information:

https://clinicaltrials.gov/study/NCT05592483?term=%09NCT05592483&rank=1